Safety and Preliminary Efficacy of Intranasal Insulin for Cognitive Impairment in Parkinson Disease and Multiple System Atrophy 1.0

File: (818 bytes)

Study_No	Group	Pharmacy	Disease	Disease_Dur	Age	Gender	Ethnicity	updrs1_base	updrs1_tre1	updrs2_base	updrs2_tre1	updrs3_base	updrs3_tre1	brady_base	brady_tre1
1	excluded							-99
2	0	1-PD	PD	3	79	1	w	15	9	14	11	32	24	13.5	11
3	1	2-PD	PD	9	64	1	w	9	9	15	15	23	23	5	5
4	0	3-PD	PD	5	53	2	w	15	15	13	13	26	23	7	7
5	1	4-PD	PD	17	71	1	a	16	16	23	23	23	23	6	6
6	0	5-PD	PD	5	56	2	w	15	16	28	28	41	52	17	23
7	0	6-PD	PD	7	66	2	w	8	14	3	3	14	7	7	2
8	1	7-PD	PD	6	66	1	w	2	2	1	3	13	1	4	0
9	1	8-PD	PD	4	64	2	w	9	5	4	3	12	6	2	3
10	0	9-PD	PD	3	56	1	w	11	10	19	16	25	41	13	17
11	1	10-PD	PD	4	65	2	w	12	12	31	32	75	73	34	34
12	1	11-PD	PD	2	60	1	w	11	6	7	4	35	23	17	8
13	0	12-PD	PD	8	63	1	w	6	8	15	13	52	36	29	17
14	excluded
15	1	14-PD	PD	10	66	1	w	9	7	12	8	35	22	17	8
16	1	1-MSA	MSA	2	50	1	w	9	8	18	20	36	34	20	18